加载中
Celcuity, Inc. operates as a cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. The firm's proprietary CELx diagnostic platform is the commercially ready technology that uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company was founded by Brian F. Sullivan and Lance G. Laing in January 2012 and is headquartered in Minneapolis, MN.
前收盘价
US$65.78
−US$5.47 · -7.68%
盘前
US$65.78
US$0.00 · 0.00%
10月8日 7:58 ET
盘中时间采用ET。市场数据可能有所延迟。
Celcuity, Inc. operates as a cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. The firm's proprietary CELx diagnostic platform is the commercially ready technology that uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company was founded by Brian F. Sullivan and Lance G. Laing in January 2012 and is headquartered in Minneapolis, MN.
日内区间
当前US$65.78
52周区间
当前US$65.78
盘中时间采用ET。市场数据可能有所延迟。
Celcuity, Inc. operates as a cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. The firm's proprietary CELx diagnostic platform is the commercially ready technology that uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company was founded by Brian F. Sullivan and Lance G. Laing in January 2012 and is headquartered in Minneapolis, MN.
日内区间
当前US$65.78
52周区间
当前US$65.78
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 销货成本 | 16.7万 USD | — | — | — | — |
| 毛利 | −16.7万 USD | — | — | — | — |
| 研究与开发 | 1.45亿 USD | 1.04亿 USD | 6059.4万 USD | 3528.95万 USD | 2575.8万 USD |
| 销售、一般及管理费用 | 2719.7万 USD | 906.37万 USD | 563.63万 USD | 438.04万 USD | 259.79万 USD |
| 营业费用 | 1.72亿 USD | 1.13亿 USD | 6623.03万 USD | 3939.11万 USD | 2835.59万 USD |
| 利息收入 | 1229.8万 USD | 1176.83万 USD | 777.76万 USD | 112.72万 USD | 1.33万 USD |
| 利息支出 | 1714.8万 USD | 1028.04万 USD | 532.64万 USD | 210.61万 USD | 126.24万 USD |
| 折旧和摊销 | 16.7万 USD | 12.99万 USD | 14.28万 USD | 21.09万 USD | 30.32万 USD |
| 营业利润 | −1.72亿 USD | −1.13亿 USD | −6623.03万 USD | −3939.11万 USD | −2835.59万 USD |
| 净利润 | −1.77亿 USD | −1.12亿 USD | −6377.91万 USD | −4037万 USD | −2960.53万 USD |
公司数据更新于 2026年10月8日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$159.88
上涨空间 143.05%报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI1.24亿0.01%2.3万亿 USD0.03%US$381.03-0.40%
State Street SPDR S&P Biotech ETFXBI8933.8万0.87%100.75亿 USD0.35%US$150.23-0.44%
iShares Russell 2000 ETFIWM7155.67万0.09%785.63亿 USD0.19%US$277.7-1.29%
Vanguard Extended Market ETFVXF3938.09万0.04%954亿 USD0.05%US$233.49-1.56%
iShares Russell 2000 Growth ETFIWO2566.64万0.18%142.49亿 USD0.24%US$355.37-1.43%
Vanguard Russell 2000 ETFVTWO1969.8万0.11%180亿 USD0.06%US$112.21-1.26%
Schwab U.S. Small-Cap ETFSCHA1520.79万0.07%216.99亿 USD0.03%US$32.61-1.47%
Vanguard Health Care ETFVHT696.21万0.03%220亿 USD0.09%US$315.31+0.78%Vanguard Morningstar Total Stock Market ETFVTIState Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHAVanguard Health Care ETFVHTAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
